Upfront, Randomized, Phase 2 Trial of Sorafenib Versus Sorafenib and Low-Dose Interferon Alfa in Patients With Advanced Renal Cell Carcinoma: Clinical and Biomarker Analysis

BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). METHODS: Untreated patients with clear cell mRCC were rand...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer
Autori principali: Jonasch, Eric, Corn, Paul, Pagliaro, Lance C., Warneke, Carla L., Johnson, Marcella M., Tamboli, Pheroze, Ng, Chaan, Aparicio, Ana, Ashe, Robynne G., Wright, John J., Tannir, Nizar M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4636203/
https://ncbi.nlm.nih.gov/pubmed/19862815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24685
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi